table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 hospitalized
COVID-19 mild to moderate
remdesivir GS-US-540-5774, 10 days GS-US-540-5774, 5 days GS-US-540-5773 ...

2 studies excluded by filtering options 0

5209 SIMPLE (Grein), 0 2300excludednot a RCTrisk of bias not avaialble
5546 remdesevir external control, 0 0130selection pending

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons